DDInter997 DDInter1376
Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and also administered in combination with other drugs for the management of CF.[L6814,L6979,L6847] Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, an ion channel involved in the transport of chloride and sodium ions across cell membranes. CFTR is active in epithelial cells of organs such as of the lungs, pancreas, liver, digestive system, and reproductive tract. Alterations in the CFTR gene result
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Ivacaftor {u} (Compound) binds {v} (Gene) CYP3A4
Ivacaftor {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A Inhibitors
Ivacaftor {u} (Compound) causes {v} (Side Effect) Pleuritic pain
Ivacaftor {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doravirine
Ivacaftor {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Ivacaftor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etonogestrel
Ivacaftor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Avapritinib
Ivacaftor {u} may lead to a major life threatening interaction when taken with {v} Fluconazole
Ivacaftor {u} may lead to a major life threatening interaction when taken with {v} Crizotinib
Ivacaftor (Compound) binds CYP3A4 (Gene)
Ivacaftor (Compound) is included by Cytochrome P450 3A Inhibitors (Pharmacologic Class)
Ivacaftor (Compound) causes Pleuritic pain (Side Effect)
Ivacaftor may cause a minor interaction that can limit clinical effects when taken with Doravirine
Ivacaftor may cause a minor interaction that can limit clinical effects when taken with Modafinil
Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Etonogestrel
Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Ivacaftor may lead to a major life threatening interaction when taken with Fluconazole
Ivacaftor may lead to a major life threatening interaction when taken with Crizotinib